martes, 26 de febrero de 2019

Is Allergan too 'sanguine' over new competition for Botox? - STAT

Is Allergan too 'sanguine' over new competition for Botox? - STAT

The Readout

Damian Garde



More reads

  • Is Allergan too ‘sanguine’ over new competition for its best-selling Botox treatment? (STAT Plus)
  • Doctors plan to test a gene therapy that could prevent Alzheimer's disease. (MIT Tech Review)
  • GE inks $21 billion biopharma sale to Danaher. (Reuters)

No hay comentarios: